AKT1 and non-small cell lung carcinoma: In addition, Terp et al. demonstrated that a combination regimen of an FGFR inhibitor and an AKT inhibitor was more effective in overcoming EGFR-TKI resistance than an FGFR inhibitor plus EGFR-TKI, suggesting that inhibition of the FGFR1-AKT pathway might be a promising strategy in EGFR-TKI-resistant NSCLC bearing FGFR1 overexpression [138].